ArticleJournal of obstetrics and gynaecology of India2025
Extended Letrozole Treatment for Ovulation Induction and Clinical Pregnancy in Conventional Treatment-resistant Polycystic Ovary Syndrome Patients: A Prospective Parallel Randomized Clinical Trial.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toxic Epidermal Necrolysis and Recurrent Implantation Failure: Unveiling a Rare Phenomenon During Pregnancy.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Polycystic ovarian syndrome (PCOS) is the most frequent cause of anovulatory infertility. Due to the high rates of ovulation and pregnancies, Letrozole (LE) has recently been considered the first-line ovulation induction medication administered to PCOS patients. Nowadays, different clinical trials have examined various LE protocol methods to reach the best strategy for infertility therapy in PCOS patients. Methods: This study was designed as a single-center, parallel randomized [1:1] clinical trial. It was registered on the World Health Organization trial registry of IRAN with registration number IRCT20110908007513N19. Eligible participants with PCOS resistant to conventional treatment were assigned to receive extended LE treatment for 7 days (group A) and 10 days (group B). Primary endpoints included ovulation rate and follicle measurements, while secondary endpoints assessed pregnancy rates and complications. A per-protocol analysis was considered. Results: Among 55 participants, the mean age was 29.27, with a BMI of 25.51. In group A, 27/27 patients were ovulated, and lastly, 10 indicated clinical pregnancy. In group B, 27/28 patients were ovulated, and only 5 indicated clinical pregnancy. While the variation in clinical pregnancy rates between the groups in our study did not achieve statistical significance, the observed trend indicates a potentially significant clinical implication. Hormone profiles, follicle sizes, and endometrial thickness did not significantly differ between clinically pregnant and non-pregnant females in both groups. No complications were observed. Conclusion: Although several conventional treatment-resistant females eventually became pregnant in a 7- or 10-day course of treatment, there are no notable differences between LE therapy in 7-day and 10-day groups. Further extensive studies are needed to validate the findings. Healthcare professionals should take this trend into account when assessing treatment alternatives, particularly within the framework of personalized patient care, as even slight enhancements in pregnancy rates can have significant effects. World Health Organization trial registry of IRAN registration number: IRCT20110908007513N19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.